Fadi Kharouf, Taraneh Tofighi, Heather N Reich, Qixuan Li, Jiandong Su, Dafna D Gladman, Zahi Touma
{"title":"血清白蛋白作为狼疮性肾炎蛋白尿恢复的早期预测因子。","authors":"Fadi Kharouf, Taraneh Tofighi, Heather N Reich, Qixuan Li, Jiandong Su, Dafna D Gladman, Zahi Touma","doi":"10.31138/mjr.040924.sai","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/purpose: </strong>Proteinuria, a slowly changing marker, is considered the best predictor of long-term renal outcomes in lupus nephritis (LN). In this study, we aimed to determine if serum albumin can serve as an early predictor of combined proteinuria recovery in LN.</p><p><strong>Methods: </strong>We studied patients diagnosed with LN with baseline and follow-up visits at 6-9 and 18-21 months. Receiver operating characteristic (ROC) curves were generated and the area under the curve (AUC) was analysed at different time points to test if serum albumin was a predictor of combined proteinuria recovery response (complete and partial proteinuria recovery, CPR+PPR) and primary efficacy proteinuria recovery (PEPR) at 6-9 and 18-21 months.</p><p><strong>Results: </strong>ROC curves for serum albumin level at baseline did not predict combined proteinuria recovery or PEPR at 6-9 or 18-21 months. However, serum albumin level at 6-9 months predicted combined proteinuria recovery at 6-9 months (AUC 0.77) and PEPR at 6-9 (AUC 0.83) and 18-21 months (AUC 0.83). Serum albumin absolute change (AUC=0.82) and percent change (AUC=0.81) from baseline to 6-9 months predicted the 6-9-month combined proteinuria recovery. Similarly, serum albumin absolute change (AUC=0.84) and percent change (AUC=0.82) from baseline to 18-21 months predicted the 18-21-month combined proteinuria recovery. A less pronounced, but similar signal was observed when PEPR was used as the endpoint at 6-9 (AUC 0.70 and 0.68, respectively) and 18-21 months (AUC 0.73 and 0.71, respectively).</p><p><strong>Conclusion: </strong>Serum albumin may serve as an accessible adjunct to proteinuria in assessing the clinical course and treatment response in LN.</p>","PeriodicalId":32816,"journal":{"name":"Mediterranean Journal of Rheumatology","volume":"36 2","pages":"242-250"},"PeriodicalIF":0.0000,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12312462/pdf/","citationCount":"0","resultStr":"{\"title\":\"Serum Albumin as an Early Predictor of Proteinuria Recovery in Lupus Nephritis.\",\"authors\":\"Fadi Kharouf, Taraneh Tofighi, Heather N Reich, Qixuan Li, Jiandong Su, Dafna D Gladman, Zahi Touma\",\"doi\":\"10.31138/mjr.040924.sai\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background/purpose: </strong>Proteinuria, a slowly changing marker, is considered the best predictor of long-term renal outcomes in lupus nephritis (LN). In this study, we aimed to determine if serum albumin can serve as an early predictor of combined proteinuria recovery in LN.</p><p><strong>Methods: </strong>We studied patients diagnosed with LN with baseline and follow-up visits at 6-9 and 18-21 months. Receiver operating characteristic (ROC) curves were generated and the area under the curve (AUC) was analysed at different time points to test if serum albumin was a predictor of combined proteinuria recovery response (complete and partial proteinuria recovery, CPR+PPR) and primary efficacy proteinuria recovery (PEPR) at 6-9 and 18-21 months.</p><p><strong>Results: </strong>ROC curves for serum albumin level at baseline did not predict combined proteinuria recovery or PEPR at 6-9 or 18-21 months. However, serum albumin level at 6-9 months predicted combined proteinuria recovery at 6-9 months (AUC 0.77) and PEPR at 6-9 (AUC 0.83) and 18-21 months (AUC 0.83). Serum albumin absolute change (AUC=0.82) and percent change (AUC=0.81) from baseline to 6-9 months predicted the 6-9-month combined proteinuria recovery. Similarly, serum albumin absolute change (AUC=0.84) and percent change (AUC=0.82) from baseline to 18-21 months predicted the 18-21-month combined proteinuria recovery. A less pronounced, but similar signal was observed when PEPR was used as the endpoint at 6-9 (AUC 0.70 and 0.68, respectively) and 18-21 months (AUC 0.73 and 0.71, respectively).</p><p><strong>Conclusion: </strong>Serum albumin may serve as an accessible adjunct to proteinuria in assessing the clinical course and treatment response in LN.</p>\",\"PeriodicalId\":32816,\"journal\":{\"name\":\"Mediterranean Journal of Rheumatology\",\"volume\":\"36 2\",\"pages\":\"242-250\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-05-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12312462/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Mediterranean Journal of Rheumatology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.31138/mjr.040924.sai\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/6/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mediterranean Journal of Rheumatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31138/mjr.040924.sai","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
Serum Albumin as an Early Predictor of Proteinuria Recovery in Lupus Nephritis.
Background/purpose: Proteinuria, a slowly changing marker, is considered the best predictor of long-term renal outcomes in lupus nephritis (LN). In this study, we aimed to determine if serum albumin can serve as an early predictor of combined proteinuria recovery in LN.
Methods: We studied patients diagnosed with LN with baseline and follow-up visits at 6-9 and 18-21 months. Receiver operating characteristic (ROC) curves were generated and the area under the curve (AUC) was analysed at different time points to test if serum albumin was a predictor of combined proteinuria recovery response (complete and partial proteinuria recovery, CPR+PPR) and primary efficacy proteinuria recovery (PEPR) at 6-9 and 18-21 months.
Results: ROC curves for serum albumin level at baseline did not predict combined proteinuria recovery or PEPR at 6-9 or 18-21 months. However, serum albumin level at 6-9 months predicted combined proteinuria recovery at 6-9 months (AUC 0.77) and PEPR at 6-9 (AUC 0.83) and 18-21 months (AUC 0.83). Serum albumin absolute change (AUC=0.82) and percent change (AUC=0.81) from baseline to 6-9 months predicted the 6-9-month combined proteinuria recovery. Similarly, serum albumin absolute change (AUC=0.84) and percent change (AUC=0.82) from baseline to 18-21 months predicted the 18-21-month combined proteinuria recovery. A less pronounced, but similar signal was observed when PEPR was used as the endpoint at 6-9 (AUC 0.70 and 0.68, respectively) and 18-21 months (AUC 0.73 and 0.71, respectively).
Conclusion: Serum albumin may serve as an accessible adjunct to proteinuria in assessing the clinical course and treatment response in LN.